SCHEMBL3432154

SCHEMBL3432154

CCc1ccc(Cn2nc(C(=O)Nc3ccc4c(c3)OCO4)c3ccccc32)nc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.51
TSHR P16473 4/20 0.49
USP2 O75604 3/20 0.49
NPSR1 Q6W5P4 3/20 0.49
ELANE P08246 1/20 0.49
ATM Q13315 1/20 0.49
KMT2A Q03164 5/20 0.47
MEN1 O00255 2/20 0.47
ALDH1A1 P00352 2/20 0.47
NPY1R P25929 1/20 0.47
NPY2R P49146 1/20 0.47
MAPT P10636 6/20 0.46
HTT P42858 2/20 0.46
GAA P10253 1/20 0.46
NPC1 O15118 4/20 0.46
NTRK1 P04629 1/20 0.45
NTRK2 Q16620 1/20 0.45
KDM4E B2RXH2 3/20 0.45
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3430664 0.89 RAB9A (0.56) RAB9ATSHRUSP2NPSR1ELANE
SCHEMBL3429942 0.86 TSHR (0.57) RAB9ATSHRUSP2NPSR1ELANE
SCHEMBL3430894 0.84 RAB9A (0.64) RAB9AUSP2KMT2AALDH1A1MAPT
SCHEMBL3427905 0.84 MAPT (0.56) RAB9ATSHRUSP2NPSR1ELANE
SCHEMBL3406432 0.84 RAB9A (0.61) RAB9ATSHRUSP2NPSR1ELANE
SCHEMBL3430604 0.83 RAB9A (0.54) RAB9ATSHRUSP2NPSR1ELANE
SCHEMBL3759853 0.82 NPSR1 (0.56) RAB9ATSHRUSP2NPSR1ELANE
SCHEMBL3427381 0.82 TSHR (0.54) RAB9ATSHRUSP2NPSR1ELANE
SCHEMBL3430712 0.82 RAB9A (0.52) RAB9ATSHRUSP2NPSR1ELANE
SCHEMBL3432147 0.82 USP2 (0.52) RAB9ATSHRUSP2NPSR1ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP claimed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US claimed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO claimed
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 RAB9A 2878/4885TSHR 2079/4885USP2 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.